Enalapril

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Enalapril

Examples of brand names: Xanef [DE]

ATC code: C09AA02

Main use (for orientation): Hypertension; heart failure

Documented research summary

Within the documented search scope, no sufficiently attributable cannabinoid pair is established for Enalapril. The structured assessment distinguishes documented drug context from the absence of specific interaction evidence. Missing data do not establish safety.

Uncertainties and limitations

Do not confuse prodrug hydrolysis with CYP activation; concomitant medicines and disease are confounders. Do not independently change prescribed medicines on the basis of this research dataset.

Structured assessment

Category: Drug context

Cannabinoid scope: No specifically substantiated pair involving a registered cannabinoid in the material assessed; no claim that all 28 cannabinoids were comprehensively reviewed simultaneously.

Evidence status: Drug properties supported by product information; insufficient evidence for a specific cannabinoid–drug pair effect.

Mechanism / drug context: Hydrolysis of enalapril to enalaprilat, followed by substantial renal excretion.

Type of supporting material: Product information and documented individual literature screening; no clinical pair trial approved for use as evidence.

Clinical interpretation: No direct cannabinoid-related change in activation or blood-pressure effects established.

Context: Complex cannabinoid hyperemesis syndrome cases are not isolated enalapril interaction experiments.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [VD_LABEL_D0214]: Original product information: drug context, not evidence for a cannabinoid–drug pair

Statement supported: Hydrolysis of enalapril to enalaprilat, followed by substantial renal excretion.

Source: ENALAPRIL MALEATE (ENALAPRIL MALEATE) TABLET [A-S MEDICATION SOLUTIONS] – DailyMed SPL [VD_LABEL_D0214]

Source role [VD_MED_42145774]: Documented research / scope-distinction context; no cannabinoid–drug pair evidence approved for use

Statement supported: Complex cannabinoid hyperemesis syndrome cases are not isolated enalapril interaction experiments.

Source: The interplay of maturity-onset diabetes of the young, obesity, uncontrolled hypertension, and cannabinoid hyperemesis in the progression to end-stage renal disease: a case report. [VD_MED_42145774]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: All individual review fields read. Original product information was rechecked only in the relevant pharmacokinetic/interaction excerpts; no complete recertification of all labels or worldwide full-text search. Literature access was based on the previously documented review; only the listed web sources were additionally read in this round. Do not confuse prodrug hydrolysis with CYP activation; concomitant medicines and disease are confounders.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[VD_LABEL_D0214] ENALAPRIL MALEATE (ENALAPRIL MALEATE) TABLET [A-S MEDICATION SOLUTIONS] – DailyMed SPL

Original source / bibliographic reference

Authors: Marketing authorisation holder / label provider according to the linked DailyMed product information

Year: 2026

Source type: Regulatory product information (US SPL)

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VD_MED_42145774] The interplay of maturity-onset diabetes of the young, obesity, uncontrolled hypertension, and cannabinoid hyperemesis in the progression to end-stage renal disease: a case report.

Original source / bibliographic reference

Authors: Ngardig Ngaba N, Lovallo V, ONeil A, Quidet XLT, Asare M, Nabeta H, Thakur S, Agyemang RO, Alataa R, Hocine FK, Rodriguez KG, Akanyijuka A, Ansah D, Amoa A, Okobi O, Khan S, Kodakandla R, Dudhat S, Tanna S, Eduardo DO, Akhter MS, Nasr R, Uday K, Misbahuddin K.

Year: 2026

Source type: Journal Article; Case Reports; case-report

DOI: 10.3389/fmed.2026.1755934

PMID: 42145774

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility